supported by funds from the National Key R&D Program of China(No.2022YFA1303600);the National Natural Science Foundation of China(No.82273423,82202501);Scientific and Technological Research Program of Chongqing Municipal Education Commission of China(No.KJQN202100429);Natural Science Foundation Project of Chongqing,China(No.CSTB2022NSCQ-MSX0864);College Young Teachers Fund of the Fok Ying Tung Education Foundation(China)(No.171100).
Human hepatitis B virus(HBV)infection is the major cause of acute and chronic hepatitis B,liver cirrhosis,and hepatocellular carcinoma.Although the application of prophylactic vaccination programs has successfully pre...
supported by grants from the National Key R&D Program of China(2022YFA1303600);the Natural Science Foundation of Chongqing(cstc2021jcyj-msxmX0298);the Science and Technology Research Program of Chongqing Municipal Education Commission(Grant No.KJZD-K202200409);the 111 Project(No.D20028),Key Laboratory of Molecular Biology on Infectious Diseases,Ministry of Education,Chongqing Medical University(No.202104);CQMU Program for Youth Innovation in Future Medicine(No.W0049).
The achievement of a functional cure for chronic hepatitis B(CHB)remains limited to a minority of patients treated with currently approved drugs.The primary objective in developing new anti-HBV drugs is to enhance the...